EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A decalogue of Molecular Tumor Board (MTB) recommendations from the CAN.HEAL Consortium

Gennaro Ciliberto, Ruggero De Maria, Patrizio Giacomini, Valentina Trapani, Martina Betti, Gabriele Bucci, Simonetta Buglioni, Lucia D'Auria, Roberta De Angelis, Arcangela De Nicolo, Celia Dupain, Nancy Frederickx und 15 weitere

European Journal of Cancer · 2025-06 · 222 · 115433

DOI: 10.1016/j.ejca.2025.115433 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2025-06. Verfasst von Gennaro Ciliberto und 26 weiteren Autor:innen. Beteiligte Einrichtung: Scientific Directorate, IRCCS National Cancer Institute Regina Elena, Rome, Italy. Hauptthemen laut MEDLINE: Neoplasms, Precision Medicine, Practice Guidelines as Topic, Medical Oncology. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerstwo Zdrowia, European Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: The CAN.HEAL consortium, comprising 47 cancer centers and academic institutions across 17 EU countries, has developed a set of recommendations for Molecular Tumor Boards (MTBs) to address the lack of standardized guidelines in personalized cancer medicine. METHODS: Over the past 2 years, through extensive collaboration and seven dedicated online meetings, CAN.HEAL experts developed consensus-based recommendations across 10 critical domains. RESULTS: The consortium agreed that MTBs' primary role is to perform molecular and clinical assessments for patients requiring care beyond standard treatment. Core MTB composition should include medical oncologists, molecular biologists, pathologists, and bioinformaticians. Patient eligibility criteria should prioritize performance status, with flexibility for rare cases. Shared informed consent is crucial for sample collection, data use, and research. A two-tiered IT workflow, with minimal and maximal datasets, is recommended, along with a comprehensive decision support tool. These recommendations focus on genomic testing, acknowledging diversity of NGS assays and proposing general guidelines. MTB reports should be concise, with technical details provided in the molecular diagnostic report. Innovative approaches like the Drug Rediscovery Protocol support access to off-label therapies. Harmonized training for MTB members is essential to bridging knowledge gaps in this evolving field. Indicators are needed to assess MTB effectiveness over time. Expanding MTB benefits to underserved populations depends on creating a shared European MTB database. CONCLUSION: Standardizing MTB practices represents a key step toward equitable access to personalized medicine and improved cancer care across Europe. Sustainable implementation requires coordinated EU efforts, and dynamic MTBs that continuously refine genomic-driven decisions within real-world contexts.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsPrecision MedicinePractice Guidelines as TopicMedical OncologyBiomarkers, TumorHumansConsensus

Stichwörter der Autor:innen

Cancer genomicsEU4HealthNGS assaysPersonalized medicinePrecision oncology

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Scientific Directorate, IRCCS National Cancer Institute Regina Elena, Rome, Italy.
  • Alleanza Contro il Cancro, Rome, Italy; Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, Rome, Italy; Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
  • UOSD Medicina di Precisione in Senologia, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.
  • Alleanza Contro il Cancro, Rome, Italy; UniCamillus - Saint Camillus International University of Health and Medical Sciences, Rome, Italy. Electronic address: trapani@alleanzacontroilcancro.it.
  • Clinical Trial Center, Biostatistics and Bioinformatics, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  • Center for Omics Sciences, IRCCS Ospedale San Raffaele, Milan, Italy.

Förderung

  • Ministerstwo Zdrowia
  • European Commission

Zitieren

APA

Ciliberto, G., De Maria, R., Giacomini, P., Trapani, V., Betti, M., Bucci, G., Buglioni, S., D'Auria, L., De Angelis, R., De Nicolo, A., Dupain, C., Frederickx, N., Genuardi, M., Indraccolo, S., Kolanowska, M., Mazzarella, L., Nowak, F., Pallocca, M., Scerri, J., …, & Le Tourneau, C. (2025). A decalogue of Molecular Tumor Board (MTB) recommendations from the CAN.HEAL Consortium. European Journal of Cancer, 222, 115433. https://doi.org/10.1016/j.ejca.2025.115433

Vancouver

Ciliberto G, De Maria R, Giacomini P, Trapani V, Betti M, Bucci G, et al. A decalogue of Molecular Tumor Board (MTB) recommendations from the CAN.HEAL Consortium. European Journal of Cancer. 2025;222:115433. doi:10.1016/j.ejca.2025.115433

BibTeX
@article{Ciliberto2025,
  author = {Ciliberto, Gennaro and De Maria, Ruggero and Giacomini, Patrizio and Trapani, Valentina and Betti, Martina and Bucci, Gabriele and Buglioni, Simonetta and D'Auria, Lucia and De Angelis, Roberta and De Nicolo, Arcangela and Dupain, Celia and Frederickx, Nancy and Genuardi, Maurizio and Indraccolo, Stefano and Kolanowska, Monika and Mazzarella, Luca and Nowak, Frederique and Pallocca, Matteo and Scerri, Jeanesse and Sgambato, Alessandro and Stoklosa, Tomasz and Van den Bulcke, Marc and Van Valckenborgh, Els and von Bubnoff, Nikolas and Zeuli, Massimo and Kamal, Maud and Le Tourneau, Christophe},
  title = {A decalogue of Molecular Tumor Board (MTB) recommendations from the CAN.HEAL Consortium},
  journal = {European Journal of Cancer},
  year = {2025},
  volume = {222},
  pages = {115433},
  doi = {10.1016/j.ejca.2025.115433}
}
Kostenlos starten →